18F-FDG PET/CT or PET role in MALT lymphoma: an open issue not yet solved. A criticalreview

Publication date: Available online 19 October 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Domenico Albano, Rexhep Durmo, Giorgio Treglia, Raffaele Giubbini, Francesco BertagnaABSTRACTMucosa associated lymphoid tissue (MALT) lymphoma is a lymphoma involving the mucosa-associated lymphoid tissue potentially arising from any mucosal site with stomach as most common site of involvement. MALT lymphoma is usually a not aggressive disease with good prognosis except of selected cases. Fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) is a non-invasive imaging tool used for staging, restaging and evaluation of treatment response innon-Hodgkin and Hodgkin lymphoma, but its effective role in MALT lymphoma is yet unclear. The open question is if these lymphomas are 18F-FDG avid or not with conflicting results present in literature and consequently the possible clinical role of 18F-FDG PET/CT in staging and restaging purposes is under debate. The aim of this review is to analyze published data about the role of 18F-FDG PET or PET/CT in patients affected by MALT lymphoma. A comprehensive computer literature search of the Scopus, Cochrane, PubMed/MEDLINE and Embase databases was conducted including articles published up to August 2019; 32 studies analyzing 18F-FDG PET or PET/CT in patients with MALT lymphoma were included. We analyzed the metabolic behaviour of MALT lymphoma at 18F-FDG PET and the impact of PET in staging, trea...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research

Related Links:

ConclusionAlthough ATC was superior to CVP, clinical outcomes (TTP, progression-free survival, and overall survival) were similar compared to BD chemotherapy for patients with grade 3A FL.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion: While providing potential clinical benefit, CAR T cell therapy utilizes resources across the therapeutic spectrum, and increasing use of this therapeutic modality can create challenges in institutional resource capacity. Identifying these resources will allow for better care delivery and allocation of funds. Further refinement of CAR T cell products and improvements in CAR T cell-related toxicity management may permit safer delivery of this therapy and reduce costs per patient. Additional analysis of resource utilization among patients treated with commercial CAR T cell products, as well as comparison with alte...
Source: Blood - Category: Hematology Authors: Tags: 902. Health Services Research-Malignant Diseases: Overuse, Costs, and Utilization of Health Services Source Type: research
Publication date: Available online 4 July 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Rustain Morgan, Mark Perry, Jennifer Kwak, Alexandria Jensen, Manali KamdarAbstractIntroductionMantle cell lymphoma (MCL) is a rare subtype of non–Hodgkin lymphoma and requires both bone marrow biopsy and fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) to correctly stage the disease at diagnosis. However, accurate identification of bone marrow involvement by lymphoma on FDG PET/CT scans has not been previously demonstrated. We hypothesized that a voxel-based analysis of...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
1428Purpose: The graded visual assessment Deauville five-point scale(5-PS) has been widely accepted to assessment in patients with Hodgkin lymphoma. The visual assessment only with PET which the unique technique can do the quantitative analysis can not show all its abilities. We want to evaluate the predictive role of the graded visual assessment Deauville five-point scale added quantitative analysis for Hodgkin lymphoma treatment. Methods: Consecutive 42 patients by Hodgkin lymphoma from our center diagnosed between December 2011 and January 2017 were retrospectively enrolled. No change to treatment based on interim-PET r...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Leukemia/Lymphoma/Myeloma Poster Session Source Type: research
Conclusions We successfully used textural features calculated from baseline 18F-FDG PET/CT scans to classify patients according to Deauville criteria and to classify lesions according to histopathology with high accuracy. Studies with larger samples are needed to verify these findings.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Leukemia/Lymphoma/Myeloma I Source Type: research
CONCLUSION. Our results show that metabolic parameters obtained on 18F-FDG PET/CT, even in at an early assessment, provide a reliable indication of treatment response in patients with HL under checkpoints inhibitors. Tumor burden modifications seem appreciable later in the course of immunotherapy, probably due to the re-activation of immune system and increased glucose consumption in the lymphocytes.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Leukemia/Lymphoma/Myeloma I Source Type: research
Conclusion Low-dose RT, administered to all sites of original involvement, was associated with improved PFS, even in the setting of a metabolic CR after ABVD. Micro-Abstract The role of consolidation radiation therapy (RT) in advanced Hodgkin lymphoma is controversial, especially if a complete response (CR) is achieved according to positron emission tomography-computed tomography imaging after chemotherapy. In this series, low-dose (approximately 20 Gy) RT to all sites of original disease improved progression-free survival, even in the setting of a CR after ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine). Long-...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Early stage classical Hodgkin lymphoma (cHL) has a high rate of cure for patients for are interim PET/CT-2 or 3 negative (1, 2) Thus, given this there is an increased focus on treatment de-escalation for patients with a negative interim PET/CT scan including decreasing number of cycles of chemotherapy, adding in biologic therapies, and decreasing radiation ranging from decreasing radiation doses and field sizes to eliminating radiation. However, for patients who have residual disease activity on interim PET/CT (1,  2) the outcomes remain challenging in that often ultimately these patients develop refractory disease th...
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
Conclusion Functional imaging techniques are increasing in popularity compared with anatomic imaging. The usage of PET-CT has emerged as a highly valuable staging and follow-up method in the treatment of HL 8 years after the introduction of PET in Lebanon. PET was used first to improve the staging, then to evaluate the treatment response, and, recently, to tailor therapy according to the response. Micro-Abstract Hodgkin lymphoma (HL) is a highly curable disease. We analyzed the data regarding the usage of PET-CT at diagnosis, during treatment (interim PET), and at the end of treatment. The first PET-CT system was introduce...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusions General clinical features were comparable with those of Western patients, whereas therapeutic outcomes were slightly inferior. The novel risk assessment model showed potential as a more powerful prognostic tool by identifying 3 subsets of patients with significantly distinct outcomes, which warrants further validations. Micro-Abstract One hundred and fifty patients with newly diagnosed Hodgkin's lymphoma at 4 medical centers over a decade were reviewed. General clinical features were comparable to western patients, while therapeutic outcomes were slightly inferior. A new risk model incorporating traditional ris...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Cancer & Oncology | Computers | CT Scan | Databases & Libraries | Hodgkin's Disease | Leukemia | Lymphoma | Myeloma | PET Scan | Study